NASDAQ
5.36USD
+0.04 (+0.75%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
532.3M
P/E
—
EPS
—
Beta
0.88
52W range
4.91-18
Day range
5.22–5.46
Open
5.32
Prev close
5.32
Volume
2.5M
Avg volume
2M
Dividend
0.00
IPO
2020-12-04
https://www.globenewswire.com/news-release/2026/08/05/3339847/3080/en/SHAREHOLDER-ALERT-Levi-Korsinsky-LLP-Notifies-Investors-It-Has-Filed-a-Complaint-to-Recover-Losses-Suffered-by-Purchasers-of-ARS-Pharmaceuticals-Inc-Securities-and-Sets-a-Lead-Plai.html · 8/5/2026-1.00
https://www.benzinga.com/news/health-care/26/07/60368241/can-ars-pharmas-new-ceo-unlock-neffys-potential · 7/9/2026-0.30
https://www.zacks.com/stock/news/2949847/strength-seen-in-crinetics-pharm-crnx-can-its-98-7-jump-turn-into-more-strength?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|daily_price_change_5%-2949847 · 7/8/2026-0.20
https://www.globenewswire.com/news-release/2026/06/30/3320167/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-ARS-Pharmaceuticals-Inc-SPRY.html · 6/30/2026
https://www.zacks.com/stock/news/2906254/ars-pharmaceuticals-inc-spry-soars-7-1-is-further-upside-left-in-the-stock?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|daily_price_change_5%-2906254 · 4/23/2026+0.80
https://seekingalpha.com/article/4870360-ars-pharmaceuticals-climbing-neffy-sales-global-expansion-could-re-rate-the-stock · 2/14/2026+0.90
https://www.defenseworld.net/2026/01/18/fas-wealth-partners-inc-buys-51460-shares-of-ars-pharmaceuticals-inc-spry.html · 1/18/2026+0.30
https://www.globenewswire.com/news-release/2025/12/29/3210899/0/en/neffy-epinephrine-nasal-spray-Approved-in-China-as-the-First-and-Only-Community-Use-Epinephrine-Product-for-the-Treatment-of-Allergic-Reactions-anaphylaxis.html · 12/29/2025+1.00
ARS Pharmaceuticals, Inc. specializes in creating ARS-1, an innovative intranasal epinephrine spray utilizing advanced absorption technology. This product serves as a crucial intervention for individuals and their households who are susceptible to life-threatening allergic reactions caused by food, pharmaceuticals, or insect stings. Among its offerings is Neffy, a low-dose version of its intranasal epinephrine nasal spray. Established in 2015, the firm operates out of San Diego, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
